Overview

ARIA (Atacand Renoprotection In NephropAthy Pt.)

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
To determine the effective dose of candesartan cilexetil for reduction of urinary protein excretion in hypertensive patients with non-diabetic chronic kidney disease with baseline urinary protein/creatinine ratio between 500mg/g and 5000mg/g, by assessing the change in urinary protein/creatinine ratio from baseline to the end of 28-week treatment
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Candesartan
Candesartan cilexetil